Anti-biofilm activity of ultrashort cinnamic acid peptide derivatives against medical device-related pathogens

The threat of antimicrobial resistance has placed increasing emphasis on the development of innovative approaches to eradicate multidrug‐resistant pathogens. Biofilm‐forming microorganisms, for example, Staphylococcus epidermidis and Staphylococcus aureus, are responsible for increased incidence of...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of peptide science 2015-10, Vol.21 (10), p.770-778
Hauptverfasser: Laverty, Garry, McCloskey, Alice P., Gorman, Sean P., Gilmore, Brendan F.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 778
container_issue 10
container_start_page 770
container_title Journal of peptide science
container_volume 21
creator Laverty, Garry
McCloskey, Alice P.
Gorman, Sean P.
Gilmore, Brendan F.
description The threat of antimicrobial resistance has placed increasing emphasis on the development of innovative approaches to eradicate multidrug‐resistant pathogens. Biofilm‐forming microorganisms, for example, Staphylococcus epidermidis and Staphylococcus aureus, are responsible for increased incidence of biomaterial infection, extended hospital stays and patient morbidity and mortality. This paper highlights the potential of ultrashort tetra‐peptide conjugated to hydrophobic cinnamic acid derivatives. These peptidomimetic molecules demonstrate selective and highly potent activity against resistant biofilm forms of Gram‐positive medical device‐related pathogens. 3‐(4‐Hydroxyphenyl)propionic)‐Orn‐Orn‐Trp‐Trp‐NH2 displays particular promise with minimum biofilm eradication concentration (MBEC) values of 125 µg/ml against methicillin sensitive (ATCC 29213) and resistant (ATCC 43300) S. aureus and activity shown against biofilm forms of Escherichia coli (MBEC: 1000 µg/ml). Kill kinetics confirms complete eradication of established 24‐h biofilms at MBEC with 6‐h exposure. Reduced cell cytotoxicity, relative to Gram‐positive pathogens, was proven via tissue culture (HaCaT) and haemolysis assays (equine erythrocytes). Existing in nature as part of the immune response, antimicrobial peptides display great promise for exploitation by the pharmaceutical industry in order to increase the library of available therapeutic molecules. Ultrashort variants are particularly promising for translation as clinical therapeutics as they are more cost‐effective, easier to synthesise and can be tailored to specific functional requirements based on the primary sequence allowing factors such as spectrum of activity to be varied. Copyright © 2015 European Peptide Society and John Wiley & Sons, Ltd. There was a rapid eradication of established two biofilms by short cinnamic–peptide hybrids within 6 h at microgram per millilitre concentrations and no significant toxicity was demonstrated. It is potential as future antimicrobial therapies to combat antimicrobial resistance.
doi_str_mv 10.1002/psc.2805
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_1722180655</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3803419421</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4915-e1df32e545859ee7799adb361fc12b0aec9d26dec678ab6852abd1b5fe7b325b3</originalsourceid><addsrcrecordid>eNpdkUtPFUEQhTtGI4gm_gIziRs3A_2gumeWeCNIIEiiRuOm048aaJwX3T1X7r-nb0BMXFUl56tK1TmEvGV0n1HKD-bk9nlD4RnZZbRtayYa9XzbK6i5ZGqHvErphtKigXxJdrgUjDaS7pLxaMyhtmHqQj9UxuWwDnlTTV219DmadD3FXLkwjmYIrujBVzPOOXisPMawNmUAU2WuTBhTrgb0wZm-aOvgsI7Ym4xlxOTr6QrH9Jq86Eyf8M1j3SPfjz99W32uz7-cnK6Ozmt32DKokflOcIRDaKBFVKptjbdCss4xbqlB13ouPTqpGmNlA9xYzyx0qKzgYMUe-fCwd47T7YIp6yEkh31vRpyWpJninDVUAhT0_X_ozbTEsVxXqOJSCwCyUO8eqcWWJ_Ucw2DiRv91sgD1A_An9Lh50hnV24R0SUhvE9KXX1fb-o8PKePdE2_iby2VUKB_XJzoj2ern-IXHOtLcQ-nyZOO</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1710895556</pqid></control><display><type>article</type><title>Anti-biofilm activity of ultrashort cinnamic acid peptide derivatives against medical device-related pathogens</title><source>MEDLINE</source><source>Wiley Online Library All Journals</source><creator>Laverty, Garry ; McCloskey, Alice P. ; Gorman, Sean P. ; Gilmore, Brendan F.</creator><creatorcontrib>Laverty, Garry ; McCloskey, Alice P. ; Gorman, Sean P. ; Gilmore, Brendan F.</creatorcontrib><description>The threat of antimicrobial resistance has placed increasing emphasis on the development of innovative approaches to eradicate multidrug‐resistant pathogens. Biofilm‐forming microorganisms, for example, Staphylococcus epidermidis and Staphylococcus aureus, are responsible for increased incidence of biomaterial infection, extended hospital stays and patient morbidity and mortality. This paper highlights the potential of ultrashort tetra‐peptide conjugated to hydrophobic cinnamic acid derivatives. These peptidomimetic molecules demonstrate selective and highly potent activity against resistant biofilm forms of Gram‐positive medical device‐related pathogens. 3‐(4‐Hydroxyphenyl)propionic)‐Orn‐Orn‐Trp‐Trp‐NH2 displays particular promise with minimum biofilm eradication concentration (MBEC) values of 125 µg/ml against methicillin sensitive (ATCC 29213) and resistant (ATCC 43300) S. aureus and activity shown against biofilm forms of Escherichia coli (MBEC: 1000 µg/ml). Kill kinetics confirms complete eradication of established 24‐h biofilms at MBEC with 6‐h exposure. Reduced cell cytotoxicity, relative to Gram‐positive pathogens, was proven via tissue culture (HaCaT) and haemolysis assays (equine erythrocytes). Existing in nature as part of the immune response, antimicrobial peptides display great promise for exploitation by the pharmaceutical industry in order to increase the library of available therapeutic molecules. Ultrashort variants are particularly promising for translation as clinical therapeutics as they are more cost‐effective, easier to synthesise and can be tailored to specific functional requirements based on the primary sequence allowing factors such as spectrum of activity to be varied. Copyright © 2015 European Peptide Society and John Wiley &amp; Sons, Ltd. There was a rapid eradication of established two biofilms by short cinnamic–peptide hybrids within 6 h at microgram per millilitre concentrations and no significant toxicity was demonstrated. It is potential as future antimicrobial therapies to combat antimicrobial resistance.</description><identifier>ISSN: 1075-2617</identifier><identifier>EISSN: 1099-1387</identifier><identifier>DOI: 10.1002/psc.2805</identifier><identifier>PMID: 26310860</identifier><identifier>CODEN: JPSIEI</identifier><language>eng</language><publisher>England: Blackwell Publishing Ltd</publisher><subject>Anti-Bacterial Agents - adverse effects ; Anti-Bacterial Agents - chemistry ; Anti-Bacterial Agents - pharmacology ; antimicrobial ; Biocompatible Materials ; biofilm ; Biofilms - drug effects ; biomaterials ; Cell Line ; Cell Survival - drug effects ; Cinnamates - chemistry ; Escherichia coli ; Hemolysis - drug effects ; Humans ; kill kinetics ; MBEC ; Microbial Sensitivity Tests ; peptide ; Peptides ; Peptides - adverse effects ; Peptides - chemistry ; Peptides - pharmacology ; Staphylococcus aureus ; Staphylococcus aureus - drug effects ; Staphylococcus epidermidis</subject><ispartof>Journal of peptide science, 2015-10, Vol.21 (10), p.770-778</ispartof><rights>Copyright © 2015 European Peptide Society and John Wiley &amp; Sons, Ltd.</rights><rights>Copyright © 2015 John Wiley &amp; Sons, Ltd.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4915-e1df32e545859ee7799adb361fc12b0aec9d26dec678ab6852abd1b5fe7b325b3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fpsc.2805$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fpsc.2805$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>315,781,785,1418,27929,27930,45579,45580</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26310860$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Laverty, Garry</creatorcontrib><creatorcontrib>McCloskey, Alice P.</creatorcontrib><creatorcontrib>Gorman, Sean P.</creatorcontrib><creatorcontrib>Gilmore, Brendan F.</creatorcontrib><title>Anti-biofilm activity of ultrashort cinnamic acid peptide derivatives against medical device-related pathogens</title><title>Journal of peptide science</title><addtitle>J. Pept. Sci</addtitle><description>The threat of antimicrobial resistance has placed increasing emphasis on the development of innovative approaches to eradicate multidrug‐resistant pathogens. Biofilm‐forming microorganisms, for example, Staphylococcus epidermidis and Staphylococcus aureus, are responsible for increased incidence of biomaterial infection, extended hospital stays and patient morbidity and mortality. This paper highlights the potential of ultrashort tetra‐peptide conjugated to hydrophobic cinnamic acid derivatives. These peptidomimetic molecules demonstrate selective and highly potent activity against resistant biofilm forms of Gram‐positive medical device‐related pathogens. 3‐(4‐Hydroxyphenyl)propionic)‐Orn‐Orn‐Trp‐Trp‐NH2 displays particular promise with minimum biofilm eradication concentration (MBEC) values of 125 µg/ml against methicillin sensitive (ATCC 29213) and resistant (ATCC 43300) S. aureus and activity shown against biofilm forms of Escherichia coli (MBEC: 1000 µg/ml). Kill kinetics confirms complete eradication of established 24‐h biofilms at MBEC with 6‐h exposure. Reduced cell cytotoxicity, relative to Gram‐positive pathogens, was proven via tissue culture (HaCaT) and haemolysis assays (equine erythrocytes). Existing in nature as part of the immune response, antimicrobial peptides display great promise for exploitation by the pharmaceutical industry in order to increase the library of available therapeutic molecules. Ultrashort variants are particularly promising for translation as clinical therapeutics as they are more cost‐effective, easier to synthesise and can be tailored to specific functional requirements based on the primary sequence allowing factors such as spectrum of activity to be varied. Copyright © 2015 European Peptide Society and John Wiley &amp; Sons, Ltd. There was a rapid eradication of established two biofilms by short cinnamic–peptide hybrids within 6 h at microgram per millilitre concentrations and no significant toxicity was demonstrated. It is potential as future antimicrobial therapies to combat antimicrobial resistance.</description><subject>Anti-Bacterial Agents - adverse effects</subject><subject>Anti-Bacterial Agents - chemistry</subject><subject>Anti-Bacterial Agents - pharmacology</subject><subject>antimicrobial</subject><subject>Biocompatible Materials</subject><subject>biofilm</subject><subject>Biofilms - drug effects</subject><subject>biomaterials</subject><subject>Cell Line</subject><subject>Cell Survival - drug effects</subject><subject>Cinnamates - chemistry</subject><subject>Escherichia coli</subject><subject>Hemolysis - drug effects</subject><subject>Humans</subject><subject>kill kinetics</subject><subject>MBEC</subject><subject>Microbial Sensitivity Tests</subject><subject>peptide</subject><subject>Peptides</subject><subject>Peptides - adverse effects</subject><subject>Peptides - chemistry</subject><subject>Peptides - pharmacology</subject><subject>Staphylococcus aureus</subject><subject>Staphylococcus aureus - drug effects</subject><subject>Staphylococcus epidermidis</subject><issn>1075-2617</issn><issn>1099-1387</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkUtPFUEQhTtGI4gm_gIziRs3A_2gumeWeCNIIEiiRuOm048aaJwX3T1X7r-nb0BMXFUl56tK1TmEvGV0n1HKD-bk9nlD4RnZZbRtayYa9XzbK6i5ZGqHvErphtKigXxJdrgUjDaS7pLxaMyhtmHqQj9UxuWwDnlTTV219DmadD3FXLkwjmYIrujBVzPOOXisPMawNmUAU2WuTBhTrgb0wZm-aOvgsI7Ym4xlxOTr6QrH9Jq86Eyf8M1j3SPfjz99W32uz7-cnK6Ozmt32DKokflOcIRDaKBFVKptjbdCss4xbqlB13ouPTqpGmNlA9xYzyx0qKzgYMUe-fCwd47T7YIp6yEkh31vRpyWpJninDVUAhT0_X_ozbTEsVxXqOJSCwCyUO8eqcWWJ_Ucw2DiRv91sgD1A_An9Lh50hnV24R0SUhvE9KXX1fb-o8PKePdE2_iby2VUKB_XJzoj2ern-IXHOtLcQ-nyZOO</recordid><startdate>201510</startdate><enddate>201510</enddate><creator>Laverty, Garry</creator><creator>McCloskey, Alice P.</creator><creator>Gorman, Sean P.</creator><creator>Gilmore, Brendan F.</creator><general>Blackwell Publishing Ltd</general><general>Wiley Subscription Services, Inc</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7QO</scope><scope>7TK</scope><scope>8FD</scope><scope>FR3</scope><scope>K9.</scope><scope>P64</scope></search><sort><creationdate>201510</creationdate><title>Anti-biofilm activity of ultrashort cinnamic acid peptide derivatives against medical device-related pathogens</title><author>Laverty, Garry ; McCloskey, Alice P. ; Gorman, Sean P. ; Gilmore, Brendan F.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4915-e1df32e545859ee7799adb361fc12b0aec9d26dec678ab6852abd1b5fe7b325b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Anti-Bacterial Agents - adverse effects</topic><topic>Anti-Bacterial Agents - chemistry</topic><topic>Anti-Bacterial Agents - pharmacology</topic><topic>antimicrobial</topic><topic>Biocompatible Materials</topic><topic>biofilm</topic><topic>Biofilms - drug effects</topic><topic>biomaterials</topic><topic>Cell Line</topic><topic>Cell Survival - drug effects</topic><topic>Cinnamates - chemistry</topic><topic>Escherichia coli</topic><topic>Hemolysis - drug effects</topic><topic>Humans</topic><topic>kill kinetics</topic><topic>MBEC</topic><topic>Microbial Sensitivity Tests</topic><topic>peptide</topic><topic>Peptides</topic><topic>Peptides - adverse effects</topic><topic>Peptides - chemistry</topic><topic>Peptides - pharmacology</topic><topic>Staphylococcus aureus</topic><topic>Staphylococcus aureus - drug effects</topic><topic>Staphylococcus epidermidis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Laverty, Garry</creatorcontrib><creatorcontrib>McCloskey, Alice P.</creatorcontrib><creatorcontrib>Gorman, Sean P.</creatorcontrib><creatorcontrib>Gilmore, Brendan F.</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>Biotechnology Research Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><jtitle>Journal of peptide science</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Laverty, Garry</au><au>McCloskey, Alice P.</au><au>Gorman, Sean P.</au><au>Gilmore, Brendan F.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Anti-biofilm activity of ultrashort cinnamic acid peptide derivatives against medical device-related pathogens</atitle><jtitle>Journal of peptide science</jtitle><addtitle>J. Pept. Sci</addtitle><date>2015-10</date><risdate>2015</risdate><volume>21</volume><issue>10</issue><spage>770</spage><epage>778</epage><pages>770-778</pages><issn>1075-2617</issn><eissn>1099-1387</eissn><coden>JPSIEI</coden><abstract>The threat of antimicrobial resistance has placed increasing emphasis on the development of innovative approaches to eradicate multidrug‐resistant pathogens. Biofilm‐forming microorganisms, for example, Staphylococcus epidermidis and Staphylococcus aureus, are responsible for increased incidence of biomaterial infection, extended hospital stays and patient morbidity and mortality. This paper highlights the potential of ultrashort tetra‐peptide conjugated to hydrophobic cinnamic acid derivatives. These peptidomimetic molecules demonstrate selective and highly potent activity against resistant biofilm forms of Gram‐positive medical device‐related pathogens. 3‐(4‐Hydroxyphenyl)propionic)‐Orn‐Orn‐Trp‐Trp‐NH2 displays particular promise with minimum biofilm eradication concentration (MBEC) values of 125 µg/ml against methicillin sensitive (ATCC 29213) and resistant (ATCC 43300) S. aureus and activity shown against biofilm forms of Escherichia coli (MBEC: 1000 µg/ml). Kill kinetics confirms complete eradication of established 24‐h biofilms at MBEC with 6‐h exposure. Reduced cell cytotoxicity, relative to Gram‐positive pathogens, was proven via tissue culture (HaCaT) and haemolysis assays (equine erythrocytes). Existing in nature as part of the immune response, antimicrobial peptides display great promise for exploitation by the pharmaceutical industry in order to increase the library of available therapeutic molecules. Ultrashort variants are particularly promising for translation as clinical therapeutics as they are more cost‐effective, easier to synthesise and can be tailored to specific functional requirements based on the primary sequence allowing factors such as spectrum of activity to be varied. Copyright © 2015 European Peptide Society and John Wiley &amp; Sons, Ltd. There was a rapid eradication of established two biofilms by short cinnamic–peptide hybrids within 6 h at microgram per millilitre concentrations and no significant toxicity was demonstrated. It is potential as future antimicrobial therapies to combat antimicrobial resistance.</abstract><cop>England</cop><pub>Blackwell Publishing Ltd</pub><pmid>26310860</pmid><doi>10.1002/psc.2805</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1075-2617
ispartof Journal of peptide science, 2015-10, Vol.21 (10), p.770-778
issn 1075-2617
1099-1387
language eng
recordid cdi_proquest_miscellaneous_1722180655
source MEDLINE; Wiley Online Library All Journals
subjects Anti-Bacterial Agents - adverse effects
Anti-Bacterial Agents - chemistry
Anti-Bacterial Agents - pharmacology
antimicrobial
Biocompatible Materials
biofilm
Biofilms - drug effects
biomaterials
Cell Line
Cell Survival - drug effects
Cinnamates - chemistry
Escherichia coli
Hemolysis - drug effects
Humans
kill kinetics
MBEC
Microbial Sensitivity Tests
peptide
Peptides
Peptides - adverse effects
Peptides - chemistry
Peptides - pharmacology
Staphylococcus aureus
Staphylococcus aureus - drug effects
Staphylococcus epidermidis
title Anti-biofilm activity of ultrashort cinnamic acid peptide derivatives against medical device-related pathogens
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-15T13%3A41%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Anti-biofilm%20activity%20of%20ultrashort%20cinnamic%20acid%20peptide%20derivatives%20against%20medical%20device-related%20pathogens&rft.jtitle=Journal%20of%20peptide%20science&rft.au=Laverty,%20Garry&rft.date=2015-10&rft.volume=21&rft.issue=10&rft.spage=770&rft.epage=778&rft.pages=770-778&rft.issn=1075-2617&rft.eissn=1099-1387&rft.coden=JPSIEI&rft_id=info:doi/10.1002/psc.2805&rft_dat=%3Cproquest_pubme%3E3803419421%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1710895556&rft_id=info:pmid/26310860&rfr_iscdi=true